company background image
NOTA logo

Novartis DB:NOTA Stock Report

Last Price

€92.40

Market Cap

€188.6b

7D

-4.1%

1Y

2.4%

Updated

12 Dec, 2024

Data

Company Financials +

NOTA Stock Overview

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details

NOTA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health4/6
Dividends5/6

Novartis AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novartis
Historical stock prices
Current Share PriceCHF 92.40
52 Week HighCHF 108.50
52 Week LowCHF 85.60
Beta0.51
1 Month Change-4.94%
3 Month Change-9.41%
1 Year Change2.44%
3 Year Change21.58%
5 Year Change8.71%
Change since IPO148.05%

Recent News & Updates

Recent updates

Shareholder Returns

NOTADE PharmaceuticalsDE Market
7D-4.1%2.6%0.3%
1Y2.4%-10.8%9.6%

Return vs Industry: NOTA exceeded the German Pharmaceuticals industry which returned -7.8% over the past year.

Return vs Market: NOTA underperformed the German Market which returned 10.3% over the past year.

Price Volatility

Is NOTA's price volatile compared to industry and market?
NOTA volatility
NOTA Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.5%

Stable Share Price: NOTA has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: NOTA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199676,057Vas Narasimhanwww.novartis.com

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
NOTA fundamental statistics
Market cap€188.61b
Earnings (TTM)€11.19b
Revenue (TTM)€47.51b

16.9x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOTA income statement (TTM)
RevenueUS$49.94b
Cost of RevenueUS$12.07b
Gross ProfitUS$37.87b
Other ExpensesUS$26.11b
EarningsUS$11.76b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 31, 2025

Earnings per share (EPS)5.88
Gross Margin75.83%
Net Profit Margin23.55%
Debt/Equity Ratio69.8%

How did NOTA perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

68%

Payout Ratio